Coagulation Cascade: Extrinsic, Intrinsic, and Common Pathways

Core Idea

Blood coagulation is triggered by tissue factor (TF) or contact activation, proceeding through extrinsic and intrinsic pathways that converge on the common pathway. The extrinsic pathway (tissue damage → TF + VII → X activation) is rapid and physiologically important. The intrinsic pathway (contact → XII → XI → IX, amplified by VIII) may be an artifact of in vitro testing. Both converge on factor X activation, leading to prothrombin (II) → thrombin (IIa) → fibrinogen → fibrin polymerization and crosslinking by factor XIII.

How It's Best Learned

Use the tissue factor pathway model, which emphasizes that tissue factor initiation is the physiologically relevant trigger. Study coagulation factor deficiencies and their clinical presentations. Understand vitamin K's role in γ-carboxylation of factors II, VII, IX, X.

Common Misconceptions

The intrinsic pathway is largely a laboratory artifact; in vivo coagulation is primarily initiated by tissue factor. Factor deficiencies in the 'intrinsic' pathway (VIII, IX, XI) cause bleeding because they amplify the TF-initiated response.

Explainer

You already understand that hemostasis involves a platelet plug followed by a fibrin mesh — the coagulation cascade is the molecular mechanism that builds that mesh. Think of the cascade as a signal amplification system: each activated factor activates many molecules of the next, so a tiny initiating signal produces an explosive burst of thrombin. Without amplification, bleeding would continue for minutes while the body slowly produced a response; with it, significant fibrin can form within seconds at a wound site.

The extrinsic pathway is the physiologically dominant trigger. When a vessel is cut, subendothelial cells that are normally hidden from blood expose tissue factor (TF) — a membrane protein that rapidly binds circulating factor VII. The TF-VIIa complex activates both factor X (entering the common pathway) and factor IX (cross-activating the intrinsic pathway's amplification arm). This TF initiation model replaced the older classroom diagram that treated both pathways as equals. The intrinsic pathway begins with factor XII activation by contact with foreign surfaces — relevant in a test tube, but patients with factor XII deficiency do not bleed abnormally because this contact activation is not the in vivo trigger. The intrinsic pathway matters clinically because factors VIII and IX (absent in hemophilia A and B) are the amplification machinery that sustains coagulation after TF initiation begins it.

The common pathway starts where both pathways converge: activated factor X pairs with factor Va as a prothrombinase complex on phospholipid surfaces (primarily activated platelet membranes) to convert prothrombin (factor II) into thrombin (factor IIa). Thrombin is the central enzyme of the whole cascade — it cleaves fibrinogen into fibrin monomers that spontaneously polymerize, and it activates factor XIII, which crosslinks fibrin polymers into a covalently bonded, mechanically strong clot. Thrombin also powerfully amplifies its own production by activating factors V and VIII upstream.

Vitamin K connects directly to this cascade in a clinically important way. Factors II, VII, IX, and X — all of which appear at critical nodes — require vitamin K-dependent γ-carboxylation to bind calcium and anchor to phospholipid surfaces. Without this modification, the prothrombinase and tenase complexes cannot assemble properly. Warfarin works by blocking vitamin K recycling, thus anticoagulating by starving these factors of their calcium-binding modification. Laboratory tests map directly onto the pathways: PT/INR tests the extrinsic and common pathways (VII, X, V, II, I) and is prolonged by warfarin; aPTT tests the intrinsic and common pathways (XII, XI, IX, VIII, X, V, II) and is prolonged in hemophilia. Knowing which pathway each factor belongs to lets you interpret these tests mechanistically rather than memorizing normal values in isolation.